At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 146 enrolled
Drug / intervention
Canagliflozin (TA-7284) +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin (TA-7284) as add-on to Insulin in Subjects With Type 2 Diabetes Mellitus
In Brief
A Phase 4 clinical trial evaluating Canagliflozin (TA-7284), Placebo, and 1 other intervention for Type 2 Diabetes Mellitus. Completed, enrolled 146 participants across 7 sites.
Detailed Summary
The purpose of this study is to evaluate the efficacy and safety of Canagliflozin (TA-7284) in combination with Insulin in patients with type 2 Diabetes for 16 weeks administration.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesJapan
Collaborators--
Timeline
Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartAug 2014
First PostedAug 2014
Primary CompletionJul 2015
TodayJul 2026
First PostedAug 20, 2014
Enrollment StartAug 1, 2014
Primary CompletionJul 1, 2015
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 11.9 years ago
Interventions
Canagliflozin (TA-7284)drug
The patients will receive Canagliflozin orally for 16 weeks
Placebodrug
The patients will receive Placebo orally for 16 weeks
Insulindrug